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After decades of intensive research, pancreatic 
adenocarcinoma (PDAC) remains a highly lethal 
disease with a median survival time that does not 
exceed 6.5 months [1]. Since more than 80% of patients 
present with advanced metastatic disease, systemic 
chemotherapy remains the only treatment. The high 
resistance to conventional and targeted therapies in 
PDAC as in other desmoplastic tumors of adults is 
largely due to the dense extracellular matrix (ECM). 
The ECM distorts blood and lymphatic vessels structure 
that hampers the possibility of systemically delivered 
therapies to reach the tumor mass [2].  
The use of engineered oncolytic viruses (OVs) is a 
promising new therapy for cancer treatment. Different 
OVs have been engineered to express immune 
stimulatory molecules indicating that OVs can act at 
two levels, by directly killing malignant cells in 
concurrence with the simultaneous activation of the host 
anti-tumor immunity. OVs can be also combined with 
chemotherapeutic agents providing an aggressive 
platform for cancer attack. One of these OVs, a Herpes 
Simplex virus named T-VEC armed with GM-CSF has 
just completed a phase III trial in advanced melanoma 
with promising results and might reach the clinic after 
FDA approval (Clinical Trials.gov Identifier 
NCT01740297). 
Conditionally Replicative Adenoviruses are oncolytic 
adenoviruses (OAV) engineered to selectively replicate 
within and kill tumor cells. Selectivity is obtained 
through the use of ‘‘cancer cell’’- specific promoters 
(CCSP) that are selected to replace viral promoters and 
drive the expression of genes essential for OAV 
replication. OAVs replicate essentially in malignant 
cells with positive expression of the gene from which 
the CCSP was selected. OAVs efficacy can be also 
improved through the exchange of the capsid fiber of 
the virus or addition of specific moieties that will 
retarget vectors to enter the cell through alternative 
receptors [3].   
As for other therapeutic modalities, viral spread and 
therapeutic efficacy is hampered by the ECM barrier. 
With this in mind, we started engineering OAVs whose 
replication was driven by CCSPs active both in the 
stroma and in the malignant compartment of the tumor 
mass. The OAV AdF512 retargeted to bind to an 
alternative  cell   surface   receptor   and  carrying  DNA  
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elements responsive to hypoxia and inflammation 
exhibited enhanced efficacy on melanoma xenografts 
made of human melanoma cells mixed with human 
fibroblasts [4]. AdF512v1 was also able to lyse fresh 
samples obtained from ovary cancer patients including 
samples refractory to chemotherapy [5]. More recently 
we have shown that the OAV AV25CDC combined 
with gemcitabine exhibited a large efficacy and 
complete absence of toxicity in preclinical models of 
pancreatic cancer in mice and syriam hamsters [6]. 
AV25CDC was able to disrupt tumor architecture by 
inducing an increase in MMP-9 activity that would have 
facilitated gemcitabine penetration deeply inside the 
tumor mass [6]. Recent studies have shown that cancer-
associated fibroblasts can render malignant cells more 
permissive to OVs infection through a cross-talk 
signaling that involves stromal and tumor derived 
factors [7].  
In addition to the efforts to improve viral dissemination 
and the secondary immune response, it is tempting to 
anticipate, as with current targeted therapies that not all 
patients will benefit from this oncolytic immune-
virotherapy. Thus, the question arises whether there is 
any possibility to predict patient response to this 
treatment. The use of patient derived xenografts (PDXs) 
is gaining momentum as a tool to predict response [8].   
In PDXs modeling, samples obtained from patient´s 
tumors or circulating tumor cells are implanted in 
immunocompromised mice either ectopically or 
orthotopically.  Once tumors grow in mice different 
treatment combinations can be implemented to establish 
the most efficacious one. From available data with other 
therapeutic modalities it appears that PDX models are 
the best preclinical model to test different combinations 
of OAVs with drugs of current use in pancreatic cancer. 
In addition, genomic firms can be obtained from 
interrogating resistant vs sensitive PDX tumors. An 
important caveat in PDAC is that nearly half of original 
tumors grow in mice, generally within two to six 
months which in some cases is coincidental with patient 
survival.  
We propose that in order to advance the field of targeted 
virotherapy it will be important to establish a procedure 
involving an initial step consisting in the assessment in 
the patient´s tumor biopsy of the expression levels of 
the viral receptor and the gene corresponding to the 
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CCSP; these data should be complemented with the in 
vitro lytic effect of the OAV on the tumor explant; in 
parallel, the therapeutic efficacy of the OAV combined 
with other treatments should be assessed in the PDXs. 
The integration of the whole data might help predict 
virus efficacy combined with other modalities to guide 
patients’ treatment. These approaches combined with 
the development of a genomic firm associated with 
sensitivity vs resistance to virus activity in the PDXs 
(and in patients) might help in selecting patients in 
advance that will benefit from OAV therapeutics. 
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